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Newborn screening for phenylketonuria (PKU) and early introduction of dietary ther-
apy has been remarkably successful in preventing the severe neurological features of
PKU, including mental retardation and epilepsy. However, concerns remain that long-
term outcome is still suboptimal, particularly in adult patients who are no longer on
strict phenylalanine-restricted diets. With our systematic literature review we aimed to
describe the neurological phenotype of adults with early-treated phenylketonuria
(ETPKU). The literature search covered the period from 1 January 1990 up to 16 April
2018, using the NLM MEDLINE controlled vocabulary. Of the 643 records initially
identified, 83 were included in the analysis. The most commonly reported neurological
signs were tremor and hyperreflexia. The overall quality of life (QoL) of ETPKU
adults was good or comparable to control populations, and there was no evidence for a
significant incidence of psychiatric disease or social difficulties. Neuroimaging
revealed that brain abnormalities are present in ETPKU adults, but their clinical signifi-
cance remains unclear. Generally, intelligence quotient (IQ) appears normal but spe-
cific deficits in neuropsychological and social functioning were reported in early-
treated adults compared with healthy individuals. However, accurately defining the
prevalence of these deficits is complicated by the lack of standardized neuropsycholog-
ical tests. Future research should employ standardized neurological, neuropsychologi-
cal, and neuroimaging protocols, and consider other techniques such as advanced
imaging analyses and the recently validated PKU-specific QoL questionnaire, to pre-
cisely define the nature of the impairments within the adult ETPKU population and
how these relate to metabolic control throughout life.
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1 | INTRODUCTION
The natural history and devastating consequences of
untreated phenylketonuria (PKU) are well described:
Abbreviations: ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; ETPKU,
early-treated phenylketonuria; HRQoL, health-related quality of life; MeSH, medical subject head-
ings; MRI, magnetic resonance imaging; Phe, Phenylalanine; PKU, phenylketonuria; QoL, quality of
life; TNO-AZL, TNO Institute of Prevention and Health and the Leiden University Hospital.
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profound neurological damage with severe intellectual
impairment and behavioral problems.1 Seizures, behavioral
problems, and movement disorders can be seen in untreated,
late diagnosed patients, and in patients with long-term diet
discontinuation.2–4 Fortunately, with early treatment and the
consequent reduction of phenylalanine (Phe) levels in the
blood and the brain, these effects are preventable.5 The
introduction of universal newborn screening has transformed
the outlook for people born with PKU, who should now be
able to lead essentially normal lives.
Individuals with early-treated PKU (ETPKU) can obtain
normal or near-normal intelligence quotient (IQ) if they main-
tain good metabolic control through dietary restriction until the
age of 10, after which IQ appears to be fixed irrespective of
Phe levels.6 Nevertheless, deficits in executive function, psy-
chiatric symptoms, and abnormalities on neuroimaging have
been reported in patients with ETPKU.7,8 However, it is
unclear whether suboptimal outcomes are related to lack of
metabolic control or to the burden of treatment. A recent retro-
spective cohort study suggests that neuropsychiatric symptoms
are more prevalent in adults with well-managed PKU than in
the general population, with many symptoms comparable with
patients with diabetes mellitus, another chronic disorder that
requires dietary restrictions.9 However, this study evaluated
data from insurance claims databases, so precise information
on treatment history was unavailable. It is not clear at this stage
what proportion of adults with ETPKU suffer from these resid-
ual effects, or to what extent they affect their lives. Recent
population-based surveys suggest that the majority of adults
with ETPKU are, in fact, functioning well in society.10,11
To develop evidence-based recommendations for the treat-
ment of adults with ETPKU, any pathological features of this
condition need to be described and the unmet medical need
defined. Currently, the neurological phenotype of early-treated
patients is not well characterized, and there are no cohort studies
which systematically describe the neurological, neurocognitive,
and neuroimaging features that can be seen, what proportion of
people are affected, and what aspects of the phenotype relate to
metabolic control. As detailed in the first European PKU guide-
lines, occasional case reports have described other problems
such as Parkinsonism and cortical blindness in individual
patients,12,13 but we do not know the prevalence of these poten-
tial complications, which might be expected to be seen primar-
ily in older patients. Therefore, we undertook a review of the
literature on neurological involvement in adult patients with
ETPKU to better understand which medical issues have been
reported in this population and to make recommendations on
appropriate outcomes to be measured in future cohort studies in
patients with ETPKU. Furthermore, we considered how neuro-
logical and neuropsychiatric involvement may affect quality of
life (QoL) and social outcomes.
2 | METHODS
2.1 | Literature retrieval and screening
strategy
A literature search of PubMed was initially performed using
NLM MEDLINE controlled vocabulary (medical subject
headings [MeSH] terms), with the MeSH term “Phenylketon-
uria” searched in conjunction with the MeSH term “Adult.”
The search was restricted to exclude individual case reports,
and include English language articles only from 1 January
1990 up to 16 April 2018 (the date of the search). Because
indexing does not always occur immediately upon an article
appearing in PubMed, a second search was performed with
free-text terms on the titles and abstracts of articles dated
1 January 2015 to 16 April 2018. The free-text terms used
were a combination of various synonyms of the initial MeSH
terms “Phenylketonurias” and “Adult.” Individual case reports
and non-English language articles were excluded. Finally, a
third search was performed to account for articles from two
relevant journals that were identified as not being indexed
within PubMed, specifically JIMD Rep and Mol Genet Metab
Rep. This search was the same as search 2, with the exception
that it included articles only from these two journals, and the
start date was set to 1 January 1990. The results from the three
searches were combined and duplicates removed.
Retrieved papers were screened to select those reporting
clinical data on behavioral, intelligence, mood, motor, neuro-
psychological, neuroimaging, neurological, psychiatric, QoL,
or social outcomes among patients with a diagnosis of PKU
(including patients with both mild PKU and classical PKU).
Papers were then excluded if no relevant data from adults with
ETPKU could be extracted (ie, data were generally excluded if
they included a contribution from late-treated patients or chil-
dren). Some rare but justifiable exceptions were allowed (eg, if
relevant data were derived from a mixed cohort with a preva-
lence of adult ETPKU patients). Certain outcomes data were
excluded if the selection of the population was intentionally
biased (eg, IQ data were excluded for matched IQ studies).
Data from patients who had discontinued dietary treatment
before the age of 5 years were excluded. However, the level of
lifetime dietary adherence (if reported) was not a criterion.
For the purpose of this review, the definition of “early
treated” is that the patient was diagnosed by newborn screen-
ing and treated pre-symptomatically, as defined by the study
in question, and the definition of “adult” is ≥16 years of age.
3 | RESULTS
Of the 643 articles retrieved from the initial search, 83 met
criteria for inclusion in this review10,11,14–94 (Figure 1).
Patients had been maintained on a Phe-restricted diet during
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early childhood, although this did not necessarily equate to
strict treatment; overall adherence to diet throughout their
lifetime was not consistently reported and was variable
between studies. Here, we discuss the key findings, with full
tables of results presented in Supporting Information,
Tables S1-S8.
3.1 | Neurological signs and symptoms
The literature search retrieved 13 articles that assessed neu-
rological signs and symptoms in adult patients with ETPKU,
of which the majority used routine clinical and neurological
examinations (Table S1).
All studies reported abnormal neurological findings in the
adult ETPKU population. The most commonly reported signs
were tremor (postural and kinetic tremor), and hyperreflexia.
Where severity of tremor was reported, it was usually mild or
moderate.32,58,59,70 Only two studies included a control group
permitting direct comparison with healthy controls. One study
with a larger sample size performed statistical evaluation but
found no statistical difference between the incidence of tremor
in patients (28%) and healthy controls (15%).59 However, in the
same study, fine motor skills were significantly impaired in
patients compared with controls for measures of hand-wrist
steadiness, dexterity and speed.59 Although rare, more severe
signs including ataxia, optic atrophy and spastic quadriparesis
were reported in one study.51
Two studies assessed the impact of Phe levels on neurologi-
cal signs.59,61 No significant difference was found in the level
of Phe control between patients with and without tremor,59 and
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FIGURE 1 PRISMA flow diagram. The stages involved in literature review are outlined, along with the number of articles included/excluded,
and the reasons for exclusion
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motor skills.59,61 However, one study that compared patients
who had never discontinued a Phe-restricted diet with those
who had discontinued found that nearly a quarter of off-diet
patients had neurological signs, relating primarily to changes in
muscle tone and deep tendon reflexes. No signs were reported
in the on-diet group, although it is important to note the small
number of patients in this group.41
4 | IQ AND
NEUROPSYCHOLOGICAL
OUTCOMES
4.1 | Intelligence quotient
The literature search identified 47 articles that presented IQ
data for adults with ETPKU. A range of standardized tests
were used, each of which was generally calibrated such that
the normal range of the general population was approxi-
mately 90 to 110 (Table S2).
Overall, while the IQ scores of adults with ETPKU were
within the normal range, they were consistently lower when
assessed in comparison to healthy subjects.32,55,59,83,92,94
Where assessed, dietary control and Phe levels at the time of
testing did not have a significant impact on IQ.17,59,60 How-
ever, several studies correlated adult IQ with historical die-
tary compliance and Phe levels, particularly in early
childhood and adolescence.58,60,74,83 IQ in patients and
healthy subjects appears to remain constant once adulthood
is reached, regardless of Phe levels.83
4.2 | Neuropsychological, executive function,
and attentional outcomes
The literature review retrieved 30 articles reporting on neu-
ropsychological, executive function, and attention findings
in adults with ETPKU (Table S3). Overall, 44 different test-
ing methods were used across the studies (Table S4), asses-
sing outcomes including working memory, sustained
attention, attentional control, and response inhibition.
A number of well-controlled studies reported statistically
significant deficits in patients compared with healthy control
groups or normative populations across a range of neuropsy-
chological and executive functions, including sustained and
selective attention,17,22,27 working memory,22,27,38 response
inhibition,46 and letter fluency.27 Two studies that performed
extensive analyses on the same cohort of patients reported
impairments in patients with ETPKU vs healthy controls, in
the higher order executive functions, visuo-spatial attention
and visuo-motor coordination, with significant variability
across patients.92,94 Additionally, a recent study reported
that compared with a control group, patients with ETPKU
showed deficits in complex language tasks and were slower
and less accurate in tasks requiring planning and strategic
abilities.89 However, two studies that assessed executive
function using the Behavior Rating Inventory of Executive
Function questionnaire reported only slightly elevated scores
compared with normative mean scores, which were not con-
sidered clinically significant.25,46
The literature provides evidence for a significant link
between the incidence of neuropsychological deficits and
elevated blood Phe levels. Where analyzed, patients who
had maintained good dietary control performed significantly
better than patients with poor dietary compliance, on mea-
sures of executive functions including working memory,
attentional control, and response inhibition.17,27,29 Perfor-
mance on focused attention and aspects of memory was also
shown to correlate with concurrent or recent Phe levels dur-
ing adulthood.22,27 By contrast, working memory was signif-
icantly improved by lower Phe levels during childhood in
adult patients adhering to a controlled diet, but showed con-
flicting results for off-diet patients.28,29 A significant associ-
ation was reported between Phe levels during childhood and
adolescence with executive functioning and executive motor
control90,91 and with information processing and sustained
attention performance in adulthood, but no change in perfor-
mance was observed after 5 years of follow-up.83
There is contradicting evidence on the effect of Phe
levels, with one study reporting significant deficits in sus-
tained attention during a high Phe condition,79 while no such
impact was reported on response inhibition78 or on cognitive
flexibility and working memory.87
The association of Phe levels with adult cognition may
depend on the age at which metabolic control was mea-
sured and on the particular cognitive domain examined.
A recent study showed that performance on verbal memory
and learning, visuomotor coordination and sustained atten-
tion were better predicted by recent Phe levels than control
during childhood, whereas performances on visuospatial
processing and complex executive functions showed a stable
association with metabolic control across different ages.94
Interestingly, a positive correlation has been found between
striatal dopamine D2/3R receptor availability, with impul-
sivity and error rate in a cognitive flexibility task, while
there was no correlation with working memory or inhibi-
tory control. These findings suggest that dopamine defi-
ciency may impact the crucial role of the prefrontal cortex
and striatum in executive functioning in adult patients with
ETPKU.87
5 | PSYCHIATRIC, MOOD, AND
BEHAVIORAL OUTCOMES
The literature search retrieved 15 articles reporting on psy-
chiatric, mood, and behavioral outcomes in adult patients
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with ETPKU (Table S5). These studies reported on a range
of psychiatric symptoms, often using standardized testing
methods that allow comparisons with normative data.
Increased incidence of psychiatric symptoms in adult
patients with ETPKU was reported in the literature, but not
consistently between studies, and there was no evidence for
an increased incidence of psychiatric diagnoses. One study
reported a significantly higher incidence of several psychiatric
symptoms among patients with PKU compared with a norma-
tive population, particularly in measures of psychoticism,
paranoid ideation, obsessive-compulsive behavior, and
depression.18 However, other studies found no significant dif-
ference between patients and control groups in the incidence
of psychiatric disorders,60 or measures of anxiety and depres-
sion.28,29 One study did find that patients with PKU experi-
enced only internalizing disturbances (emotional problems
such as depression and anxiety), while healthy controls exhib-
ited both internalizing and externalizing disturbances (inter-
personal problems such as antisocial behavior) equally.60
Regarding sleep behavior, one study reported that adult
patients with ETPKU presented more sleep disorders, reduced
sleep quality, increased latency to fall asleep, and more day-
time sleepiness compared with first degree relatives.88
Average Phe levels have been reported to be significantly
correlated with scores for psychoticism and psychiatric symp-
tom intensity,18 while better Phe control during childhood was
associated with better mood during adulthood.30 Similarly,
depression and anxiety scores were positively correlated with
the age at diet initiation and childhood Phe levels, respec-
tively.22,90 Equally, in other studies, psychiatric disturbance,
anxiety, and depression were neither associated with current
dietary status, nor with concurrent or historical Phe levels.28,60
Interestingly, one study found that patients with good dietary
control during childhood reported a higher incidence of psy-
chiatric disorders than those with poor dietary control, which
the authors suggest may be attributed to the psychological
stress incurred by adherence to a strict diet.49 Similarly,
another study found that a restrictive and controlling parenting
style was a risk factor for the development of psychiatric
symptoms,60 although the relationship between parenting style
and dietary adherence was not assessed.
6 | QUALITY OF LIFE
The literature search retrieved 11 articles reporting on QoL in
adult patients with ETPKU. Several different questionnaires
were used to asses QoL, however, only one article included a
validated PKU-specific assessment19 (Table S6).
Several studies used standardized QoL tests, which
reported good QoL in patients, comparable with that of
healthy controls.21,26,30,54,76 However, specific QoL domains
may be affected in adults with PKU, despite normal scores
overall. For example, patients scored significantly lower
than controls only on the cognitive functioning domain of
the TNO-AZL Adult QoL questionnaire.31 Furthermore,
compared with the US general population, adult patients
with PKU scored consistently worse in mental domains of
the short form-36 questionnaire, while they achieved better
scores on the physical domains.19 Elsewhere, the difference
in physical and mental domain scores between patients and
healthy controls was nonsignificant.28,29 Additionally, one
study reported significantly lower QoL in male vs female
patients, and in patients with lower educational level, despite
a normal QoL score in the overall population.26
Bosch et al evaluated health-related QoL (HRQoL) in
mild-to-moderate and classical PKU patients (determined by
Phe range at diagnosis), using a validated PKU-specific
questionnaire designed to assess the impact of PKU on a
patient's life. Using this questionnaire, patients with mild-to-
moderate PKU tended to report a lower emotional, practical,
social, and financial impact of PKU compared with patients
with classical PKU.19 However, the impact of dietary man-
agement on QoL was comparable between patients with
classical and mild PKU, possibly reflecting dietary relaxa-
tion during adulthood.19 In another study, patients on a
restricted diet reported higher scores of general life-
satisfaction than both an off-diet patient group and a refer-
ence sample.10 Moreover, some data suggest that returning
to a strict diet after discontinuation for at least 3 months can
significantly improve the subjective well-being of patients,
according to evaluation with the Psychological General
Well-Being Index.16
7 | SOCIAL OUTCOMES
Overall, the literature search identified 15 articles that
reported on social outcomes in adult patients with ETPKU,
variously assessed by standardized questionnaires and stan-
dard clinical interviews (Table S7).
Several studies reported comparable sociodemographic
outcomes between patients and control populations, includ-
ing comparisons with healthy siblings, in terms of employ-
ment, marital status, having children, education, and
professional occupation.10,11,20,21,41 Additionally, no statisti-
cally significant difference was reported between patients
and controls in the achievement of autonomy, psychosexual,
and social developmental milestones.20,21
When compared with patients with galactosemia, patients
with PKU scored significantly better on psychosexual and
social development, and were more frequently cohabiting/
married and in employment,20 suggesting that the outcomes
of dietary treatment of PKU are better than those seen in
galactosemia.
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Two studies that provided comparative German census data
did report differences in educational attainment between sub-
jects with PKU and the general population. In the first study,
patients with PKU, 96% of whom were on a restricted diet,
achieved lower levels of academic achievement, specifically
for graduation at senior high school level, compared with the
general population.54 The second study found that educational
attainment was only lower in patients with PKU whose treat-
ment was interrupted (for at least 4 years starting at the age of
7-14 years), while patients who had been continuously treated
until the end of adolescence demonstrated comparable educa-
tion status to the census population.10 Nevertheless, income
was comparable between patients with PKU and the census
population, regardless of therapy interruption.10,54
Although evidence for the relationship between Phe levels
and social outcomes is limited, some studies indicated that
social factors in adult life are related to metabolic control during
childhood,11,54 while one study found that social skills are not
associated with concurrent Phe level.38 There is also evidence
to suggest that the demands of maintaining a low Phe diet itself
may restrict a patient's lifestyle and social interactions.34
8 | NEUROIMAGING
The literature review retrieved 35 publications reporting
magnetic resonance imaging (MRI) findings in adult patients
with ETPKU (Table S8). Most articles assessed white matter
abnormalities using T2-weighted imaging.
In patients with ETPKU, overt atrophy is rare and con-
ventional MRI typically discloses increased signal on
T2-weighted images within periventricular white matter
regions,32,63,75 brain stem, and cerebellum.63
Other MRI techniques have also been used to report dif-
ferences between PKU patients and healthy subjects.
Diffusion-weighted imaging (DWI) provides evidence for
significantly reduced apparent diffusion coefficient (ADC)
in patients, demonstrating impaired water diffusion,32,48,80
which may indicate higher cell-packing density compared
with controls.33 Additionally, analysis of T2-relaxation
reported markedly longer values in patients, indicating
increased water content relative to controls,32 although this
may be specific to patients with poor dietary control.33 Brain
volume may also be affected in patients with PKU, particu-
larly with reductions of the cerebrum, pons, hippocampus,
and corpus callosum regions compared with controls.58
The results provide contradicting evidence for a relation-
ship between dietary adherence and the severity of brain
abnormalities. In one study, patients who had never discon-
tinued a restricted diet tended to exhibit less severe white
matter abnormalities than those who had discontinued or had
a history of poor dietary control.75 However, another study
reported abnormalities despite the fact that all patients had
adhered to dietary treatment since birth.48 Additionally, the
severity of brain abnormalities were generally associated
with historical Phe levels,30,50,55 while there appeared to be
no relationship with Phe concentration at the time of MRI
evaluation.51 Furthermore, there was no significant correla-
tions between the volumes of different brain structures and
current or historical Phe levels.58
MR spectroscopy studies have repeatedly detected abnor-
mal concentrations of brain Phe45,84 that may be specifically
associated with white matter abnormalities.41,84 Interest-
ingly, one study reported that milder white matter abnormal-
ities were associated with lower brain Phe levels, but not
blood Phe levels.41 Furthermore, a significant negative cor-
relation between brain Phe levels and ADC was found to be
specific to the corpus callosum.80 Recently, two-dimensional
shift correlated spectroscopy has been applied for the unam-
biguous quantification of cerebral metabolites, Phe and tyro-
sine, that present spectral overlap via conventional
spectroscopy. With this technique, brain concentrations of
these metabolites were significantly associated with some
indices of neuropsychological functioning (eg, auditory
memory and executive functioning).81
9 | CONCLUSIONS
The introduction of newborn screening means that people
born with PKU can be expected to lead essentially normal
lives. While patients who have been treated since birth may
suffer some residual morbidity, the extent to which this
affects the adult population is poorly characterized. This arti-
cle represents the first systematic review to report on a
strictly adult population of patients with ETPKU.
9.1 | Neurological
To date, there is little evidence for clinically relevant neuro-
logical morbidity in this early and continuously treated pop-
ulation of adults with PKU. It seems unlikely that the minor
neurological signs and symptoms that have been described
would have a negative effect on patients' everyday lives.
Nevertheless, to confirm any relationship between Phe levels
and neurological signs and symptoms, future studies should
consistently test neurological functioning alongside Phe
levels for every patient. Furthermore, there should be an
effort to understand the temporal association of Phe levels
with outcomes; for example, whether there are periods of life
when the brain is particularly vulnerable to the effects of
high Phe levels, and whether fluctuating Phe levels have dif-
ferent effects to stable Phe levels.
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9.2 | IQ and neuropsychological outcomes
Although, on average, IQ in ETPKU adults appears to be
within the normal range, significant deficits were reported in
a number of neuropsychological, executive functions, speed,
and attentional outcomes. An accurate summary of the neu-
ropsychological deficits seen in this early treated population
was made difficult by the wide range of different assess-
ments used and the limited population studied: a survey into
adult PKU management found that only 26% of healthcare
providers perform routine neurocognitive tests in all of their
adult patients.95 However, the choice over the best neuro-
psychological test to use may be difficult to make in routine
clinical practice. An easily administered test, such as BRIEF,
may be well accepted by patients, but may not be sensitive
enough to detect the subtle deficits reported in patients with
ETPKU, nor to detect any new information after a short
follow-up period. Conversely, a more sophisticated test may
provide improved sensitivity, but would be more difficult to
administer and be less likely to be accepted by patients,
resulting in limited value for clinical purposes. To precisely
define the neuropsychological phenotype of adult patients
with PKU, a consensus needs to be reached on an appropri-
ate testing battery and the timing for administration.
9.3 | Psychiatric, mood, behavioral, and social
outcomes
Issues with mood and social functioning were found more
often than deficits of executive function in ETPKU adults38,79;
however, there is no evidence that adults with ETPKU have a
significantly higher incidence of psychiatric, mood, behav-
ioral, or social problems than the general population. Never-
theless, the incidence of certain mood and behavioral
outcomes, especially anxiety, could be further explored in
future studies. Furthermore, evidence for the impact of dietary
restriction on these outcomes was inconsistent. Further
research into the psychiatric and social outcomes of adults
with PKU should focus on understanding if there is a direct
correlation between Phe levels and psychosocial difficulties,
or whether such difficulties that patients experience are caused
by the demands of maintaining a restricted diet.
9.4 | Quality of life
Assessing the impact of ETPKU on QoL are limited by the
fact that all but one of the articles retrieved from the litera-
ture used generic HRQoL assessments, which may not be
sensitive enough to detect any specific problems related to
PKU. Future research should utilize the recently developed
PKU-QoL questionnaire that is specifically designed to
assess the impact of PKU on all aspects of a patient's life.
This includes evaluating the social and emotional impact of
PKU, as well as the impact of adhering to dietary restrictions
and supplements.96
9.5 | Neuroimaging
The pathogenesis of white matter abnormalities in PKU is
not yet fully understood, therefore, the mechanism that links
brain white matter abnormalities to possible cognitive
impairment is difficult to unravel. Conventional brain MRI
(FLAIR/T2-weighted imaging and DWI) represents a power-
ful, readily available, noninvasive tool for detecting brain
changes in adult patients with ETPKU. Although routine
MRI data currently have limited use in informing treatment
decisions, future research may use regular examinations to
monitor white matter changes in people with PKU as they
age. Furthermore, a recent morphometric MRI study in a
mixed population of adults and children showed gray matter
volume reductions in the parietal and occipital cortex of
patients with ETPKU.97 This indicates that brain MRI
changes in patients with ETPKU are not only confined to
the white matter, highlighting the importance of performing
brain MRI to better understand the disease. Advanced MRI
quantitative techniques, which have already provided valu-
able pathogenic clues about brain involvement in ETPKU,
are promising tools in the search for biomarkers, not only
for investigating the efficacy of new treatments in a research
setting but also, hopefully, in tailoring individual treatment
to prevent irreversible brain injury.
10 | SUMMARY AND CONCLUDING
REMARKS
This review of the current literature, excluding case reports,
has found studies which show minor neurological findings;
white matter changes on MRI; subtle but significant deficits
in neuropsychological functions; an increased, but nonsig-
nificant, incidence of psychiatric symptoms and possible
social difficulties in selected populations of adults with
ETPKU. Overall, however, these individuals have a good
QoL and social and educational achievements similar to
those of the general population. The fact that individuals
with PKU are now leading normal lives is testimony to the
success of newborn screening and the early institution of
dietary therapy.
It is likely that some patients do have significant impair-
ments that impact on their everyday function and it is not
unreasonable for patients, physicians, and parents to worry
that they, their patient or their child will be at risk. However,
the current evidence does not indicate that there are long-
term PKU-related health problems that are serious and irre-
versible. A better understanding of the impact of Phe levels
on the precise range and frequency of problems seen in
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adults with PKU will help to further develop the evidence-
based approach to treatment guidelines, and make sure that
patients have the best chances of realizing the full benefits
of treatment while minimizing any adverse effects of overly
strict management.
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